EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deciphering the Heterogeneity of Cancer-Associated Fibroblasts in Prostate Cancer: From Stromal Biology to Clinical Translation

Ho Trong Tan Truong iD, Whi-An Kwon iD, Hyeong Jung Woo, Minseok S Kim, Nhu Quang Tran iD, Jae Young Joung

Cancers · 14.05.2026 · 18 (10) · 1600

DOI: 10.3390/cancers18101600 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.05.2026. Verfasst von Ho Trong Tan Truong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) progression and treatment resistance are driven by tumor-intrinsic mechanisms and adaptive remodeling of the tumor microenvironment, in which cancer-associated fibroblasts (CAFs) play a crucial role. Although CAF biology is increasingly recognized, a major translational gap remains: CAFs are highly heterogeneous, and comprise distinct functional states with divergent effects on disease progression, immune regulation, and therapeutic resistance. To bridge this gap, we synthesize evidence from single-cell and spatial transcriptomic studies, tissue-based pathology, liquid biopsy assays, and molecular imaging to construct an evidence-tiered, decision-oriented translational framework that connects stromal mechanisms, translational measurement strategies, and therapeutic interventions in PCa. Single-cell and spatial transcriptomic analyses have consistently identified multiple CAF programs, including matrix-remodeling, inflammatory, immunoregulatory, antigen-presenting, and therapy-imprinted states, each with distinct functional outputs and clinical correlates. Tissue-based readouts, including reactive stromal grade (RSG) and fibroblast activation protein (FAP) immunohistochemistry, provide practical proxies for stromal activation and correlate with disease-specific mortality and imaging phenotypes. Circulating CAFs (cCAFs) represent an emerging liquid biopsy modality for longitudinal stromal monitoring, although technical standardization is required before clinical implementation. FAP-targeted PET imaging and emerging dual prostate-specific membrane antigen (PSMA)/FAP-targeted theranostic strategies provide noninvasive tools for patient selection and response assessment, particularly in PSMA-discordant or tracer-heterogeneous disease. Androgen receptor (AR)-targeted therapy can reprogram stromal states toward resistance-promoting circuits, highlighting the dynamic and plastic nature of the CAF compartment. A state-based CAF framework organizes stromal biology into testable translational hypotheses rather than immediate clinical standards. RSG and FAP-based tissue or imaging readouts are practical markers of stromal activation, whereas spatial CAF-immune signatures and cCAF assays remain investigational and require assay harmonization and prospective validation. Future trials should pre-specify stromal biomarkers as enrichment or pharmacodynamic variables when matched to the intervention and should avoid treating CAFs as a uniform therapeutic target.

Schlagwörter

Stichwörter der Autor:innen

cancer-associated fibroblastscastration-resistant prostate cancerfibroblast activation proteinliquid biopsyprostate cancersingle-cell analysisspatial transcriptomicstumor microenvironment

Autor:innen und Institutionen

  • Department of Urology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam.
  • Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
  • Research Institute of Precision Medicine and Geroscience, Myongji Medical Foundation, Goyang 10475, Republic of Korea.
  • Department of New Biology, DGIST, Techno Jungang-Daero 333, Daegu 42988, Republic of Korea.
  • CTCELLS Inc., Seoul 06307, Republic of Korea.
  • Department of Urology, Urological Cancer Center, National Cancer Center, Goyang 10408, Republic of Korea.

ORCID-Profile: Ho Trong Tan Truong, Whi-An Kwon, Nhu Quang Tran

Förderung

  • National Cancer Center

Zitieren

APA

Truong, H. T. T., Kwon, W. A., Woo, H. J., Kim, M. S., Tran, N. Q., & Joung, J. Y. (2026). Deciphering the Heterogeneity of Cancer-Associated Fibroblasts in Prostate Cancer: From Stromal Biology to Clinical Translation. Cancers, 18(10), 1600. https://doi.org/10.3390/cancers18101600

Vancouver

Truong HTT, Kwon WA, Woo HJ, Kim MS, Tran NQ, Joung JY. Deciphering the Heterogeneity of Cancer-Associated Fibroblasts in Prostate Cancer: From Stromal Biology to Clinical Translation. Cancers. 2026;18(10):1600. doi:10.3390/cancers18101600

BibTeX
@article{Truong2026,
  author = {Truong, Ho Trong Tan and Kwon, Whi-An and Woo, Hyeong Jung and Kim, Minseok S and Tran, Nhu Quang and Joung, Jae Young},
  title = {Deciphering the Heterogeneity of Cancer-Associated Fibroblasts in Prostate Cancer: From Stromal Biology to Clinical Translation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1600},
  doi = {10.3390/cancers18101600}
}
Kostenlos starten →